These findings indicate that MYC proteins are required for both tumor initiation and maintenance of the malignant phenotype and corroborate the notion that indirect inhibition of MYCN by targeting Brd-proteins or Aurora A is a promising therapeutic strategy in MYCN-dependent tumors across entities. The gene discussed is MYC; the disease is neoplasm.